Amicus Therapeutics to Announce Fourth Quarter and Full-Year 2011 Financial Results on February 13, 2012

Published on Wednesday, 08 February 2012 09:36 Written by TradersHuddle Staff

CRANBURY, N.J., Feb. 8, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Monday, February 13, 2012 at 5 p.m. ET to discuss financial results for the fourth quarter and full-year ended December 31, 2011.

The call with be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team.

Interested participants and investors may access the conference call at 5 p.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).

A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.

A telephonic replay of the call will be available for seven days beginning at 8 p.m. ET on February 13, 2012. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 50733384.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program migalastat HCl is in Phase 3 for the treatment of Fabry disease.

FOLD-G

CONTACT: Investors/Media
         Sara Pellegrino
         
 This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
 
         (609) 662-5044